This site is intended for health professionals only

UCB Board of Directors candidates announced


UCB today announces Harriet Edelman and Charles-Antoine Janssen as candidates to be appointed as new members of UCB’s Board of Directors at UCB’s next General Assembly.

By the next General Assembly on April 26, 2012, the mandates of Karel Boone, Thomas Leysen and Gaëtan van de Werve will come to an end. Alexandre Van Damme has notified his resignation. 

Roch Doliveux, CEO of UCB, said: “Karel Boone, Thomas Leysen, Alexandre Van Damme and Gaëtan van de Werve have served very successfully as UCB Board members and we would like to thank them for their key contribution and healthy challenges. Special tribute and thanks go to Karel B

oone, our Chairman who has reached the statutory age limit. Karel has thoughtfully stimulated and supported UCB’s transformation since 2000″. 

Gerhard Mayr who is to succeed Karel Boone as Chairman of the Board of Directors of UCB said : “we are delighted to have Harriet and Charles-Antoine as new candidates. Both bring unique experience and views to the Board, enabling us to continue our journey as a patient-centric biopharma leader.”

Harriet Edelman is currently Vice Chairman of Emigrant Savings Bank and has responsibility for Finance Operations and Information Technology. Harriet has been with the bank since 2008 and, prior to that, was employed at Avon Products, Inc., a leading global beauty company with over $10 billion in annual revenue. 

Harriet held a number of leadership roles at Avon Products throughout her career, including Senior Vice President & Chief Information Officer, Senior Vice President, Global Supply Chain and numerous prior executive positions in Marketing, Sales and Customer Service. 

Harriet serves as a director of Brinker International, Inc., an owner, operator and franchisor of restaurants, Ariba, Inc., a provider of supply chain procurement and spend management solutions, and serves on the Board of Trustees at Bucknell University and the New York Blood Center. Harriet holds a bachelor’s degree from Bucknell University and a Master of Business Administration from Fordham University.

Charles-Antoine joined UCB in 2001 where he held several management positions at global and local levels. Among other responsibilities he was head of Business Development, General Manager of Austria and India, and most recently managedInternational Major Markets Operations. 

Prior to UCB, Charles-Antoine worked for Merrill Lynch in London from 1996-2000 where he was Vice-President Equities Research then Vice-President New Derivatives Europe. He holds a bachelor of Laws degree from Brussels University (ULB) and an AMP from Harvard Business School. 

Today Charles-Antoine Janssen teaches social entrepreneurship and sustainable development at the Solvay Brussels School of Management and Economics, Brussels University (ULB). Over the years, Charles-Antoine has volunteered with several non-profit organisations and launched various societal wealth creation initiatives.

Both candidates as Board members have been selected with a view to further broaden the skills of the Board and to align it with the changing and demanding environment. 

Subject to the approval of the proposed resolutions by the General Assembly, the new Board would include seven Independent Board members namely: Bert De Graeve, Harriet Edelman, Peter Fellner, Jean-Pierre Kinet, Tom McKillop, Gerhard Mayr (Chairman), and Norman Ornstein. Five other members of the Board would not be independent : Evelyn du Monceau (Vice Chair) Roch Doliveux (Executive Director), Charles-Antoine Janssen, Arnoud de Pret and Bridget van Rijckevorsel.


Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine